Rezolute Proposes Public Offering of Common Stock and Pre-Funded Warrants

Rezolute, Inc., a late-stage biopharmaceutical firm listed on Nasdaq under the ticker RZLT, has announced the initiation of a public offering involving its common stock or pre-funded warrants to purchase its common stock. The offering is to be managed by Jefferies and Cantor, who will act as the principal underwriters. Additionally, Rezolute plans to grant the underwriters a 30-day option to buy up to 15% more shares than initially offered, including shares underlying pre-funded warrants.

The success and specifics of this public offering are contingent on various market conditions, and there is no guaranteed completion date or assurance of the final size and terms. All shares in this offering will be issued by Rezolute itself.

A registration statement concerning the securities to be offered was filed with and declared effective by the Securities and Exchange Commission (SEC) on November 29, 2023. The offering will proceed only through a prospectus supplement and an accompanying prospectus, both part of the registration statement. A preliminary prospectus supplement will be filed with the SEC and will be accessible through the SEC's website. Physical copies of these documents can be obtained from Jefferies LLC and Cantor Fitzgerald & Co. in New York, with specific contact details provided for requests.

It is important to note that this announcement is not an offer to sell or a solicitation to buy these securities in jurisdictions where such activities would be illegal prior to proper registration or qualification under applicable securities laws.

Rezolute focuses on developing groundbreaking treatments for severe rare diseases. One of its leading therapies, the antibody RZ358, targets various forms of hyperinsulinism (HI), including congenital and tumor-induced hyperinsulinism, and has demonstrated considerable efficacy in clinical studies and practical applications.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!